AstraZeneca in collaboration with Indian Society of Nephrology, launches CKD Academy
Top nephrologists to mentor medical professionals
AstraZeneca India announced the launch of the Chronic Kidney Disease Academy, in collaboration with the largest professional organization of nephrologists in India – the Indian Society of Nephrology (ISN). This academy will offer module-based learning for clinicians to enable them to provide better kidney care to their patients. The training programme aims to cover the pathophysiology, presentation, diagnosis, complications and management of CKD. The announcement comes after the partnership agreed between both organisations earlier this year on World Kidney Day, to create public awareness about kidney care and related health disorders, build education at the primary care physician level on early diagnosis, prompt management and aid nationwide screening for at-risk patients and the general public to promote timely detection and holistic management.
Through this programme, AstraZeneca and the Indian Society of Nephrology aim to help clinicians and healthcare practitioners to provide holistic kidney care to their patients. Under World Kidney Day’s theme of ‘Kidney Health For All’, both organisations have strengthened their commitment to the purpose of generating large-scale awareness and educating people about ways to improve kidney health.
Dr A K Bhalla, President, Indian Society of Nephrology and Chairman, Department of Nephrology at Sir Gangaram Hospital said, “With AstraZeneca and top nephrologists, we are working locally and nationally to deliver accurate health information, address the current burden of CKDs and improve the clinical outcomes for patients.”
Dr Sanjeev Gulati, President Elect – Indian Society of Nephrology and Principal Director, Nephrology and Kidney Transplant at Fortis Escorts said, “With the intervention of AstraZeneca as a knowledge partner in our fight against CKDs, we are constantly invested in bridging the knowledge gap with the community for better kidney care. ”
Dr Anil Kukreja, Vice President – Medical Affairs and Regulatory, AstraZeneca India, said “By thoroughly educating the clinicians about the prevention, progression and management of chronic kidney diseases, we aim to reduce the associated mortality and morbidity rate in India. Together with ISN, we will be able to sensitize and thrust awareness on early detection, which is crucial to slow down the progression of CKDs, to improve long-term health outcomes.”
The certificate training course on CKD’s latest updates will train about 1000 primary care physicians through three interactive modules. The modules would chronologically focus on the burden and risk factors of CKD, followed by the holistic guidelines for the management of CKD and lastly on newer therapies for better CKD management with a focus on SGLT2i inhibitors.
These modules will be delivered by 30 eminent nephrologists from across the country, who will serve as faculty for this programme. The faculty shall be available both online and offline for mentoring young nephrologists and aiding scientific support. The modules will be one hour each and will be delivered by the faculty members in three to four months duration over virtual mode. On completing the three modules, a certificate of participation that will be endorsed by AstraZeneca and ISN will be provided to all participants.
